PT  - JOURNAL ARTICLE
AU  - KAZUMI HAYASHI
AU  - MIHO TAMURA
AU  - EIJIRO NAGASAKI
AU  - YUKIKO YOSHII
AU  - TAKAYUKI ISHIGAKI
AU  - TAKASHI KAZAMA
AU  - MAKIKO KAMIO
AU  - HIROKO NOGI
AU  - YASUO TORIUMI
AU  - HIROSHI TAKEYAMA
AU  - SHINGO YANO
TI  - A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer
AID  - 10.21873/anticanres.14994
DP  - 2021 Apr 01
TA  - Anticancer Research
PG  - 2193--2195
VI  - 41
IP  - 4
4099  - http://ar.iiarjournals.org/content/41/4/2193.short
4100  - http://ar.iiarjournals.org/content/41/4/2193.full
SO  - Anticancer Res2021 Apr 01; 41
AB  - Background/Aim: Since January 2020, coronavirus disease (COVID-19) cases have been confirmed in Japan, and the number of patients with COVID-19 has been increasing. Two emergency declarations have been made previously and one is currently in effect. Based on our experience of a situation that could affect cancer treatment, this study retrospectively examined the correlation between perioperative anticancer therapy and COVID-19 incidence in patients with breast cancer. Patients and Methods: Patients who underwent perioperative anticancer therapy for breast cancer at our hospital from February 2020 to February 2021 were included in this study. The presence or absence of COVID-19, timing of anticancer drug initiation, and clinical data were collected. Results: No cases of COVID-19 were diagnosed in patients receiving perioperative anticancer therapy at our hospital. Conclusion: Regimen modification, active use of supportive care, and patient lifestyle were factors reducing the incidence of COVID-19.